New OTC Opportunity Rextovy nasal spray launch and FDA approval for over‑the‑counter opioid overdose treatment present a direct sales and channel expansion opportunity for pharmacy chains, online retailers, and consumer health channels seeking ready-to-use overdose management products.

Major Acquisition Tie The $1.08B Baqsimi acquisition from Eli Lilly expands Amphastar’s low blood sugar drug portfolio, signaling capacity for large‑scale distribution partnerships, contract manufacturing for injectables or nasal sprays, and potential cross‑sell with diabetes care suppliers.

Global Manufacturing Footprint Five manufacturing facilities across the US, China, and Europe plus a dedicated New Drug Research Center enable scalable contract manufacturing and regional regulatory support, offering sales opportunities for CDMOs, partner manufacturers, and co‑development deals.

Quality and Compliance Emphasis on cGMP‑compliant US production aligns with customers prioritizing high‑quality finished products, creating a selling point for partners seeking reliable supply chains, auditable quality systems, and US‑based manufacturing for domestic or export markets.

Strategic Engagement Active participation in high‑profile healthcare conferences and investor events signals ongoing business development and visibility to potential buyers, licensors, and collaborators; leverage these touchpoints to arrange meetings with pharma distributors and healthcare providers.